DK3378859T3 - Benzofuranderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf i medicin - Google Patents
Benzofuranderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf i medicin Download PDFInfo
- Publication number
- DK3378859T3 DK3378859T3 DK16865671.8T DK16865671T DK3378859T3 DK 3378859 T3 DK3378859 T3 DK 3378859T3 DK 16865671 T DK16865671 T DK 16865671T DK 3378859 T3 DK3378859 T3 DK 3378859T3
- Authority
- DK
- Denmark
- Prior art keywords
- benzofurand
- medicine
- derivatives
- preparing
- benzofurand derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510800975 | 2015-11-19 | ||
| PCT/CN2016/104318 WO2017084494A1 (zh) | 2015-11-19 | 2016-11-02 | 苯并呋喃类衍生物、其制备方法及其在医药上的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3378859T3 true DK3378859T3 (da) | 2020-01-20 |
Family
ID=58717310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16865671.8T DK3378859T3 (da) | 2015-11-19 | 2016-11-02 | Benzofuranderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf i medicin |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10759787B2 (da) |
| EP (1) | EP3378859B1 (da) |
| JP (1) | JP6828229B2 (da) |
| KR (1) | KR20180081587A (da) |
| CN (1) | CN107428742B (da) |
| AU (1) | AU2016357900B2 (da) |
| BR (1) | BR112018007876B1 (da) |
| CA (1) | CA3002436A1 (da) |
| DK (1) | DK3378859T3 (da) |
| ES (1) | ES2760510T3 (da) |
| HK (1) | HK1243414A1 (da) |
| HR (1) | HRP20192209T1 (da) |
| HU (1) | HUE047785T2 (da) |
| LT (1) | LT3378859T (da) |
| MX (1) | MX2018005019A (da) |
| PL (1) | PL3378859T3 (da) |
| PT (1) | PT3378859T (da) |
| RS (1) | RS59763B1 (da) |
| RU (1) | RU2727198C2 (da) |
| SI (1) | SI3378859T1 (da) |
| TW (1) | TWI718207B (da) |
| WO (1) | WO2017084494A1 (da) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
| WO2018210302A1 (zh) | 2017-05-18 | 2018-11-22 | 江苏恒瑞医药股份有限公司 | 一种苯并呋喃类衍生物游离碱的晶型及制备方法 |
| TWI810185B (zh) | 2017-05-18 | 2023-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種ｅｚｈ２抑制劑與ｂｔｋ抑制劑聯合在製備治療腫瘤的藥物中的用途 |
| JP7295105B6 (ja) * | 2017-11-10 | 2023-07-24 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | ベンゾフラン誘導体の製造方法 |
| CA3089639C (en) | 2018-01-31 | 2024-06-18 | Mirati Therapeutics, Inc. | Imidazo[1,2-c]pyrimidinyl compounds as prc2 inhibitors |
| CN110179796B (zh) * | 2018-02-23 | 2023-01-24 | 江苏恒瑞医药股份有限公司 | 一种苯并呋喃类衍生物的组合物及制备方法 |
| PL3781561T3 (pl) * | 2018-04-18 | 2024-07-22 | Constellation Pharmaceuticals, Inc. | Modulatory enzymów modyfikujących grupę metylową, kompozycje i ich zastosowania |
| CN110563722A (zh) * | 2018-06-06 | 2019-12-13 | 上海青煜医药科技有限公司 | 吡啶或哒嗪并环化合物及其应用 |
| TW202027787A (zh) * | 2018-09-29 | 2020-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | Ｅｚｈ２抑制劑與免疫檢查點抑制劑聯合在製備治療腫瘤的藥物中的用途 |
| EP3950676A4 (en) | 2019-03-25 | 2022-08-10 | Shanghai Synergy Pharmaceutical Sciences Co., Ltd | METHOD FOR THE PREPARATION OF AMIDE COMPOUND AND ITS APPLICATION IN THE FIELD OF MEDICINE |
| CN113302185B (zh) * | 2019-04-29 | 2024-04-09 | 上海和誉生物医药科技有限公司 | 苯并呋喃-6-甲酰胺衍生物、其制备方法和药学上的应用 |
| CN110003187B (zh) * | 2019-05-10 | 2021-11-05 | 南京工业大学 | 一种多氟烷基取代苯并呋喃类化合物及其制备方法 |
| WO2020228591A1 (zh) * | 2019-05-10 | 2020-11-19 | 江苏恒瑞医药股份有限公司 | 一种6-取代氨基苯并呋喃化合物的制备方法 |
| CN110172448B (zh) * | 2019-05-30 | 2020-07-28 | 中南大学湘雅二医院 | 一种滑膜肉瘤细胞系hSS-005R及其子代细胞系 |
| CN112007162B (zh) * | 2019-05-30 | 2023-05-12 | 江苏恒瑞医药股份有限公司 | Ezh2抑制剂与免疫检查点抑制剂、vegfr抑制剂联合在制备治疗肿瘤药物中的用途 |
| WO2020259667A1 (zh) * | 2019-06-28 | 2020-12-30 | 江苏恒瑞医药股份有限公司 | Tlr激动剂与抗ox40抗体或其抗原结合片段联合在制备治疗肿瘤的药物中的用途 |
| KR20220041130A (ko) | 2019-07-24 | 2022-03-31 | 콘스텔레이션 파마슈티칼스, 인크. | 암 치료를 위한 병용 요법에서의 ezh2 억제 |
| WO2021063331A1 (zh) * | 2019-09-30 | 2021-04-08 | 江苏恒瑞医药股份有限公司 | EZH2抑制剂与含有TGF-β受体的融合蛋白联合在制备治疗肿瘤的药物中的用途 |
| TW202126302A (zh) * | 2019-09-30 | 2021-07-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | Ｅｚｈ２抑制劑與免疫檢查點抑制劑、酪胺酸激酶抑制劑聯合在製備治療腫瘤藥物中的用途 |
| TW202114670A (zh) * | 2019-09-30 | 2021-04-16 | 大陸商江蘇恒瑞醫藥股份有限公司 | 一種ezh2抑制劑與cdk4/6抑制劑聯合在製備治療腫瘤藥物中的用途 |
| CN112870365A (zh) * | 2019-11-29 | 2021-06-01 | 江苏恒瑞医药股份有限公司 | Ezh2抑制剂和/或parp抑制剂与化疗药物联合在制备治疗肿瘤药物中的用途 |
| MX2024002538A (es) | 2021-08-30 | 2024-03-19 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Uso de un inhibidor de la ezh2 en la preparacion de farmacos para el tratamiento del linfoma de linfocitos t. |
| CN118055928A (zh) | 2021-10-15 | 2024-05-17 | 江苏恒瑞医药股份有限公司 | 一种苯并呋喃衍生物的制备方法 |
| WO2023244917A1 (en) | 2022-06-13 | 2023-12-21 | Treeline Biosciences, Inc. | 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders |
| WO2023244918A1 (en) | 2022-06-13 | 2023-12-21 | Treeline Biosciences, Inc. | Quinolone bcl6 bifunctional degraders |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110275630A1 (en) | 2003-06-02 | 2011-11-10 | Abbott Laboratories | Isoindolinone kinase inhibitors |
| JP2011512341A (ja) * | 2008-02-14 | 2011-04-21 | エフ．ホフマン−ラ ロシュ アーゲー | 抗ウイルス性複素環化合物 |
| ES2528269T3 (es) * | 2010-05-07 | 2015-02-06 | Glaxosmithkline Llc | Azaindazoles |
| RS55874B1 (sr) * | 2010-05-07 | 2017-08-31 | Glaxosmithkline Llc | Indoli |
| ES2534804T3 (es) | 2010-05-07 | 2015-04-28 | Glaxosmithkline Llc | Indazoles |
| EP2410171A1 (en) | 2010-07-23 | 2012-01-25 | Ewt Ip B.V. | Wind turbine having a rotor with hub |
| SG180031A1 (en) | 2010-10-15 | 2012-05-30 | Agency Science Tech & Res | Combination treatment of cancer |
| AU2012223448B2 (en) * | 2011-02-28 | 2017-03-16 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| TWI598336B (zh) * | 2011-04-13 | 2017-09-11 | 雅酶股份有限公司 | 經取代之苯化合物 |
| US9073924B2 (en) * | 2011-09-13 | 2015-07-07 | Glaxosmithkline Llc | Azaindazoles |
| JP2014534178A (ja) * | 2011-09-30 | 2014-12-18 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | 癌の処置方法 |
| WO2013067300A1 (en) | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Method of treatment |
| WO2013173441A2 (en) | 2012-05-16 | 2013-11-21 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
| PE20151981A1 (es) | 2013-04-30 | 2016-01-14 | Glaxosmithkline Ip No 2 Ltd | Pontenciador de inhibidores del homologo de zeste |
| WO2015077194A1 (en) * | 2013-11-22 | 2015-05-28 | Bristol-Myers Squibb Company | Inhibitors of lysine methyl transferase |
| SI3121175T1 (sl) | 2014-03-17 | 2020-07-31 | Daiichi Sankyo Company, Limited | Derivati 1,3-benzodioksola kot EZH1 in/ali EZH2 inhibitorji |
-
2016
- 2016-11-02 WO PCT/CN2016/104318 patent/WO2017084494A1/zh active Application Filing
- 2016-11-02 SI SI201630514T patent/SI3378859T1/sl unknown
- 2016-11-02 BR BR112018007876-0A patent/BR112018007876B1/pt active IP Right Grant
- 2016-11-02 KR KR1020187016692A patent/KR20180081587A/ko not_active Application Discontinuation
- 2016-11-02 PT PT168656718T patent/PT3378859T/pt unknown
- 2016-11-02 CA CA3002436A patent/CA3002436A1/en active Pending
- 2016-11-02 ES ES16865671T patent/ES2760510T3/es active Active
- 2016-11-02 RU RU2018119173A patent/RU2727198C2/ru active
- 2016-11-02 DK DK16865671.8T patent/DK3378859T3/da active
- 2016-11-02 US US15/775,958 patent/US10759787B2/en active Active
- 2016-11-02 MX MX2018005019A patent/MX2018005019A/es unknown
- 2016-11-02 RS RS20191628A patent/RS59763B1/sr unknown
- 2016-11-02 AU AU2016357900A patent/AU2016357900B2/en active Active
- 2016-11-02 CN CN201680013259.7A patent/CN107428742B/zh active Active
- 2016-11-02 HU HUE16865671A patent/HUE047785T2/hu unknown
- 2016-11-02 EP EP16865671.8A patent/EP3378859B1/en active Active
- 2016-11-02 JP JP2018523005A patent/JP6828229B2/ja active Active
- 2016-11-02 PL PL16865671T patent/PL3378859T3/pl unknown
- 2016-11-02 LT LTEP16865671.8T patent/LT3378859T/lt unknown
- 2016-11-16 TW TW105137422A patent/TWI718207B/zh active
-
2018
- 2018-03-01 HK HK18102969.3A patent/HK1243414A1/zh unknown
-
2019
- 2019-12-09 HR HRP20192209TT patent/HRP20192209T1/hr unknown
-
2020
- 2020-07-22 US US16/935,407 patent/US11059811B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3378859T3 (da) | Benzofuranderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf i medicin | |
| DK3354649T3 (da) | Oxaspiroderivat, fremstillingsmetode derfor og anvendelser deraf i lægemidler | |
| DK3453707T3 (da) | Benzazepinderivat, fremgangsmåde til fremstilling, farmaceutisk sammensætning og anvendelse deraf | |
| DK3209308T3 (da) | Aktiverede bifidobakterier og fremgangsmåder til anvendelse deraf | |
| DK3643709T3 (da) | Isoindolinderivat, mellemprodukt, fremgangsmåde til fremstilling, farmaceutisk sammensætning og anvendelse deraf | |
| DK3153169T3 (da) | Fremgangsmåde til behandling af tumor, farmaceutisk sammensætning og medicinæskesæt | |
| DK3486242T3 (da) | Oxopicolinamidderivat, fremgangsmåde til fremstilling deraf og farmaceutisk anvendelse deraf | |
| DK3505519T3 (da) | Pyridinamin-substituerede heterotricyclo-forbindelser, fremstilling deraf og anvendelse i medicin | |
| DK3265043T3 (da) | Hjælpemiddel til patienttransport og -træning | |
| DK3259597T3 (da) | Pvrig-polypeptider og fremgangsmåder til behandling | |
| DK3310805T3 (da) | Pd-1-cd28-fusionsproteiner og anvendelse deraf i medicin | |
| DK3559000T3 (da) | Benzimidazol-derivater, fremgangsmåder til fremstilling og anvendelser deraf | |
| DK3394065T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf | |
| DK3094640T3 (da) | Fremgangsmåder til steril kromatografi og fremstilling | |
| DK3305310T3 (da) | Onkolytisk virusformulering og fremgangsmåde til fremstilling deraf | |
| DK3380525T3 (da) | Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf | |
| DK3357343T3 (da) | Fedtsammensætning og fremgangsmåde til fremstilling heraf | |
| DK3183201T3 (da) | Spilsamling og fremgangsmåde til anvendelse | |
| DK3185872T3 (da) | Formulering af testosteron og metoder til behandling hermed | |
| DK3495482T3 (da) | Fremgangsmåde til fremstilling af dna-enhedssammensætning og fremgangsmåde til frembringelse af concatenat-dna | |
| DK3404024T3 (da) | Quinazolinonderivat, fremgangsmåde til fremstilling deraf, farmaceutisk sammensætning og anvendelser | |
| DK3353191T3 (da) | Cykliske polypeptider, fremgangsmåde til opnåelse deraf og terapeutisk anvendelse deraf | |
| DK3212166T3 (da) | Varme-steriliseret formulering omfattende chitosan og fremgangsmåde til fremstilling deraf | |
| DK3057589T3 (da) | (s)-pirlindol og farmaceutisk acceptable salte heraf til anvendelse i medicin | |
| DK3387019T3 (da) | Relaxin-immunoglobulinfusionsproteiner og anvendelsesfremgangsmåder |